James C. Yao

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.1Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Epidemiology of Neuroendocrine Neoplasms in the US

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.15798

Top 18%

1.1DataRank

Top 18%72 citations

Katrine L. Wallace, Daniel M. Halperin, Jessica Maxwell, Pamela L. Kunz, Simron Singh +3 more

Papers

Driven by 27 papers — median percentile 0. Top paper: “Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)”.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Journal of Clinical Oncology(2022)10.1200/jco.22.01013

N/A

4.9DataRank · unranked

297 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +14 more

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

The Lancet. Gastroenterology & hepatology(2022)10.1016/s2468-1253(21)00427-1

N/A

4.7DataRank · unranked

263 citations

Elshad Hasanov, Hop Sanderson Tran Cao, Lianchun Xiao, Jean‐Nicolas Vauthey, Sunyoung S. Lee +24 more

Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors

JAMA Oncology(2022)10.1001/jamaoncol.2022.0212

N/A

1.1DataRank · unranked

40 citations

Suyu Liu, Arvind Dasari, David R. Fogelman, Priya Bhosale, Armeen Mahvash +21 more

Epidemiology of Neuroendocrine Neoplasms in the US

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.15798

Top 18%

1.1DataRank

Top 18%72 citations

Katrine L. Wallace, Daniel M. Halperin, Jessica Maxwell, Pamela L. Kunz, Simron Singh +3 more

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0331

N/A

0DataRank · unranked

73 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu +29 more

Mechanisms of socioeconomic differences in COVID-19 screening and hospitalizations

PLoS ONE(2021)10.1371/journal.pone.0255343

N/A

0DataRank · unranked

17 citations

Douglas Gunzler, Vardhmaan Jain, Adam T. Perzynski, Neal V. Dawson, Douglas Einstadter +12 more

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials

Cancer(2021)10.1002/cncr.33540

N/A

0DataRank · unranked

11 citations

Carlo Carnaghi, Roberto Buzzoni, Juan W. Valle, Fabian Herbst, Antonia Ridolfi +5 more

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

Oncotarget(2021)10.18632/oncotarget.27924

N/A

0DataRank · unranked

3 citations

Sunyoung Lee, Lianchun Xiao, Manal M. Hassan, Aliya Qayyum, Rikita Hiatia +12 more

Trends in total and out-of-pocket cost of cancer care around the first year of diagnosis for the four most common cancers among privately insured nonelderly adults: 2009-2016.

Journal of Clinical Oncology(2021)10.1200/jco.2020.39.28_suppl.5

N/A

0DataRank · unranked

1 citations

Ying Xu, Cathy J. Bradley, Sharon H. Giordano, James C. Yao, K. Robin Yabroff +1 more

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

Frontiers in Oncology(2022)10.3389/fonc.2022.986305

N/A

0DataRank · unranked

24 citations

Abedul Haque, Deeksha Vishwamitra, Manal M. Hassan, Lianchun Xiao, Bhawana George +11 more

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Scientific Reports(2020)10.1038/s41598-020-58366-z

N/A

0DataRank · unranked

20 citations

Filip Jankú, Sarina A. Piha‐Paul, Kenneth R. Hess, Russell R. Broaddus, Lidong Liu +11 more

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4004

N/A

0DataRank · unranked

21 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +15 more

Bioprosthetic valve monitoring in patients with carcinoid heart disease

Frontiers in Cardiovascular Medicine(2023)10.3389/fcvm.2022.1072890

N/A

0DataRank · unranked

5 citations

Saamir Hassan, Anita Deswal, Joerg Herrmann, Juhee Song, Dominique Monlezun +17 more

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad096

N/A

0DataRank · unranked

9 citations

Thomas A. Hope, Emily B Bergsland, Lisa Bodei, David Bushnell, Jennifer A. Chan +63 more

Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features

The Oncologist(2023)10.1093/oncolo/oyad329

N/A

0DataRank · unranked

1 citations

Russell G. Witt, Khaled M. Elsayes, Ali Baiomy, Lianchun Xiao, Sarah Palmquist +14 more

Data from Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity

(2023)10.1158/0008-5472.c.6500708

N/A

0DataRank · unranked

0 citations

Yong Gao, Liwei Wang, Qiang Li, Jun Zhang, Xiangdong Le +6 more

Supplementary Materials and Methods from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

Figshare(2023)10.1158/1078-0432.22446608.v1

Top 100%

0DataRank

Top 100%0 citations

Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins +10 more

Supplementary Materials and Methods from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2023)10.1158/1078-0432.22446608

Top 100%

0DataRank

Top 100%0 citations

Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins +10 more

Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

(2023)10.1158/2159-8290.c.6549433.v1

N/A

0DataRank · unranked

0 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu‐Chin Fu +29 more

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

Cancer Biomarkers(2024)10.3233/cbm-230431

N/A

0DataRank · unranked

12 citations

Sunyoung S. Lee, Tarık Demir, Shadi Chamseddine, Zishuo Ian Hu, Lianchun Xiao +17 more

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma

Journal of Immunotherapy and Precision Oncology(2024)10.36401/jipo-24-6

N/A

0DataRank · unranked

8 citations

Betül Gök Yavuz, Yehia I. Mohamed, Sunyoung S. Lee, James C. Yao, Zishuo Ian Hu +13 more

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma(2024)10.2147/jhc.s452564

N/A

0DataRank · unranked

2 citations

Michael LaPelusa, Lianchun Xiao, Yehia I. Mohamed, Sunyoung Lee, Zishuo Hu +8 more

Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study

Oral Oncology(2024)10.1016/j.oraloncology.2024.106747

N/A

0DataRank · unranked

2 citations

S. Liu, Priya Bhosale, Mehmet Altan, W. Darbonne, Katja Schulze +14 more

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Oncotarget(2022)10.18632/oncotarget.28322

N/A

0DataRank · unranked

17 citations

Dan G. Duda, Muhammad O. Awiwi, Sunyoung S. Lee, Lina Altameemi, Lianchun Xiao +13 more

IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e16660

N/A

0DataRank · unranked

1 citations

Aliya Qayyum, Manal M. Hassan, Lianchun Xiao, Dan G. Duda, Rikita Hatia +9 more

IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.488

N/A

0DataRank · unranked

0 citations

Aliya Qayyum, Manal M. Hassan, Lianchun Xiao, Dan G. Duda, Rikita Hatia +8 more

Financial burden of discarded weight-based cancer drugs to payers and patients in private insurance market.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7083

N/A

0DataRank · unranked

0 citations

Ying Xu, Hui Zhao, James C. Yao, Ya‐Chen Tina Shih

James C. Yao

Indexed papers

Top data-sharing exemplar

Papers